What Promethazine Compound Linctus Treats: Main Uses and Benefits

This multi-component preparation is commonly used across domains where additional symptomatic support is needed. The therapeutic classes involved are designed to assist with managing multi-symptom cold and allergy issues. This medication is commonly used for conditions presenting with acute episodes, such as acute upper respiratory infections, the common cold, and seasonal allergies (allergic rhinitis).

It is relevant for managing symptom clusters that include a troublesome, non-productive cough, nasal and sinus congestion, sneezing, and excessive rhinorrhea. This combination is considered relevant for easing symptoms that create noticeable physiological strain during episodes of heightened discomfort. It is often applied during phases when symptoms interfere with daily functioning and helps maintain a sense of stability when symptoms are more prominent.

“This preparation is used for managing symptoms related to physical discomfort, such as cough and congestion, that may interfere with functional stability.”

Quick Fact: Relief for Multi-Symptom Discomfort The linctus is relevant for easing symptoms that cluster together, such as when a persistent dry cough coexists with allergic manifestations and airway congestion.

Regulatory References

1. Hong Kong Drug Office guidance on Oral Cough and Cold Medicines

Who Can and Cannot Use Promethazine Compound Linctus?

Eligibility for this medication is strictly defined by regulatory age thresholds and pre-existing health conditions, as documented by health authorities.

Absolute Contraindications

The linctus is strictly contraindicated for use in two specific populations:

• Pediatric patients less than 2 years of age due to the high risk of potentially fatal respiratory depression.
• Any individual with a known hypersensitivity or idiosyncratic reaction to promethazine or other related phenothiazine medicines.
• Patients who are in comatose states.

Respiratory and Comorbidity Restrictions

The medicine is contraindicated for the treatment of lower respiratory tract symptoms, including asthma, and use should be avoided in patients with compromised breathing, such as those with COPD or sleep apnea.

Use is defined as conditional and requires caution in several other populations. This includes individuals with cardiovascular disease, impairment of liver function, seizure disorders, and conditions impacted by anticholinergic effects, such as narrow-angle glaucoma or prostatic hypertrophy.

Specific Population Status

The drug is not recommended for use by individuals who are breastfeeding. For pregnant women, the use of this linctus requires caution, aligning with its classification status.

Interactions with Other Medicines and Products

The following section details clinically significant drug, food, and product interactions officially documented in regulatory information for Promethazine (a key component of the Linctus).

Pharmacodynamic and Contraindicated Interactions

Pharmacokinetic and Procedural Interactions

Population Considerations: Regulatory documents note that elderly patients are particularly susceptible to the enhanced CNS depression and anticholinergic effects when Promethazine is combined with relevant agents. Use in children under two years old is contraindicated.

Promethazine, a phenothiazine derivative, functions primarily as a competitive inverse agonist at central and peripheral Histamine H1 receptors. This interaction stabilizes the H1 receptor in its inactive conformation, thereby preventing the binding and action of endogenous histamine. Intracellularly, this inhibition modulates the downstream Gq/ PLC/ IP3/ Ca^2+ signaling cascade, altering cellular responsiveness. In the central nervous system, this H1 antagonism, particularly within the tuberomammillary nucleus, leads to system-level modulation of wakefulness and arousal pathways. Promethazine also acts as a non-selective competitive antagonist at muscarinic acetylcholine receptors ( M1 in particular) and as an antagonist at mesolimbic and chemoreceptor trigger zone dopamine D2 receptors, contributing to its multifaceted physiological modulation.

Administration Protocol

Promethazine Compound Linctus is an oral liquid preparation, and the Oral route is the sole official administration method. As a compound solution, it is typically available in a concentration formulated to deliver 6.25 mg promethazine and 15 mg dextromethorphan in a 5 mL dose.

Dosing Schedule and Frequency

The standard adult dosing regimen is 5 mL of the solution, which is administered every 4 to 6 hours as needed for temporary symptom relief. It is a procedural requirement that the total volume administered must not exceed 30 mL within any 24-hour period. The official guidance permits the solution to be taken with or without food; if gastric discomfort is a concern, administration with food or a glass of water is allowed.

Procedural and Age-Specific Rules

Accurate measurement is a required component of the administration protocol. The dose must be measured using a marked oral dosing device (such as a syringe or measuring spoon), as household teaspoons are not considered accurate for the specified volume.

Regarding specific populations, the preparation is contraindicated for use in children younger than 2 years of age. For older children (aged 6 to 12 years), official regimens typically prescribe a lower dose of 2.5 to 5 mL every 4 to 6 hours, which must not exceed a lower 24-hour maximum. If a dose is missed and it is nearly time for the next dose, the missed dose should be skipped to maintain the scheduled regimen.

Promethazine Compound Linctus: Recent Clinical Evidence

Overview of Research Scope

Promethazine, the active antihistamine component in Promethazine Compound Linctus, has been used clinically for many decades. Due to its long-standing presence, recent clinical trials often focus on specific patient populations or examine its comparative effects against newer agents, rather than establishing its initial efficacy for common indications such as allergic reactions or mild cough suppression. Research commonly explores the safety profile, particularly in relation to central nervous system depression.

Findings Related to Cough and Allergy

Studies examining cough relief often evaluate the effects of the compound formulation, which may include expectorants or decongestants in addition to promethazine. The effectiveness of the linctus formulation for cough suppression is primarily attributed to the antihistamine's sedative properties, which may decrease the cough reflex sensitivity. However, formal, large-scale randomized controlled trials (RCTs) specifically comparing the compound linctus against modern, non-sedating antihistamines for general allergy symptoms or viral cough are limited.

Safety and Pharmacovigilance Data

Recent pharmacovigilance data consistently highlight the risk of drowsiness and sedation as the most commonly reported adverse effects associated with promethazine use. Due to its known effects on the central nervous system, research has focused on its use in vulnerable populations, such as the elderly, where it may be associated with an increased risk of falls or impaired cognitive function. Regulatory warnings emphasize avoiding the product in very young children due to the potential for fatal respiratory depression.

Key Studies & References

1. Promethazine - StatPearls - NCBI Bookshelf

Common questions about Promethazine Compound Linctus (FAQ)

Q: What is the difference between Promethazine Compound Linctus and other common cough syrups?

A: Regulatory documents describe Promethazine Compound Linctus as a multi-component preparation containing three active ingredients. These ingredients are an antihistamine (Promethazine), an antitussive or cough suppressant (Dextromethorphan), and a decongestant (Ephedrine). Other common cough syrups may contain a different combination of ingredients, or fewer components, depending on their intended purpose.

Q: Does Promethazine Compound Linctus contain an opioid like codeine?

A: Official information defines the active components of this formulation as Promethazine, Dextromethorphan, and Ephedrine. The drug is classified as a combination of an antihistamine, an antitussive, and a sympathomimetic amine. Opioid medications, such as codeine, are not listed as active ingredients in this formulation.

Q: How long is the linctus good for after the bottle has been opened?

A: Official storage instructions provided by health authorities typically advise using the linctus within a specific timeframe after the bottle is first opened, such as 3 months. This timeframe is provided to help ensure the medicine's stability and quality. Always refer to the specific guidance provided on the product packaging.

Q: Does Promethazine Compound Linctus interact with herbal supplements?

A: Regulatory guidance may state that there is not enough data to confirm the safety of taking all herbal supplements alongside this medicine. It is described that taking it with products that also cause side effects like sleepiness or dry mouth could increase the risk of these effects.

Q: Is there a risk of becoming dependent on Promethazine Compound Linctus if used for a long time?

A: The ingredient Promethazine is not classified as an opioid or controlled substance in official documents. However, one of the active ingredients, Dextromethorphan, has documented potential for abuse when used in quantities that are much higher than the recommended therapeutic doses. The regulatory documentation describes this product as being intended for short-term symptomatic relief.

Q: Can Promethazine Compound Linctus be taken with medications for anxiety or depression?

A: Regulatory documents note that caution is required because this medicine can cause significant additive effects when combined with Central Nervous System (CNS) depressants. Many medicines used for anxiety and depression are classified as CNS depressants. Additionally, it is strictly prohibited for use within 14 days of taking Monoamine Oxidase Inhibitors (MAOIs).

Q: What information is available about using Promethazine for symptoms of motion sickness?

A: The Promethazine component in the linctus is officially recognized by regulatory bodies for its antiemetic (anti-nausea) properties. Consequently, anti-motion sickness effects are a recognized and documented use of Promethazine in some official contexts.

Q: Does this medicine have a known effect on the severity of seizures or the seizure threshold?

A: Official warnings note that Promethazine is associated with a lowering of the seizure threshold. Due to this reported effect, regulatory bodies advise that the product should be used with caution in individuals with a pre-existing history of seizure disorders.

Q: Can women use Promethazine Compound Linctus during pregnancy?

A: Official regulatory guidance suggests that the use of this linctus during pregnancy requires caution. Some health authorities may state that while the medicine can be taken, other medications may be preferred depending on the stage of pregnancy.

Q: Is Promethazine Compound Linctus considered safe to use while breastfeeding?

A: Official documents generally state that use of this medicine is not recommended while breastfeeding. There is a documented potential for the infant to experience sedation, as the medicine may pass into breast milk.

Q: Does this medicine contain sugar or affect blood sugar levels?

A: Some liquid forms of this medication may contain sugar or other types of sweeteners. Official cautions advise that the medicine may affect blood sugar levels, which is a consideration for individuals with diabetes.

Q: What should I do if the linctus appears cloudy or discolored?

A: Official product information instructs that the linctus should be visually inspected for any discoloration or the formation of particles before it is administered. If the product appears cloudy, discolored, or any particles are visible, regulatory instructions are that the product should be discarded.

Q: Is there a risk of developing vivid dreams or nightmares while taking this linctus?

A: Nightmares, delirium, and agitated behavior are documented in official prescribing information as adverse events. These are sometimes categorized as 'paradoxical reactions' associated with the use of the Promethazine component.

Q: What is the difference between Promethazine Compound Linctus and Promethazine DM syrup?

A: The difference lies in the number of active ingredients. Promethazine DM syrup typically contains two active ingredients: Promethazine (antihistamine) and Dextromethorphan (antitussive). Promethazine Compound Linctus contains those two, plus a third active component, Ephedrine (a decongestant).

Q: Does the linctus cause changes in appetite or weight?

A: Official regulatory product information lists both a loss of appetite and changes in body weight among the possible reported adverse reactions associated with the use of this medicine.

How to Store and Dispose of Promethazine Compound Linctus?

Promethazine Compound Linctus must be stored strictly according to official regulatory labeling to ensure product stability and safety.

Storage Requirements

Store the linctus at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container and the container must remain tightly closed.

• Protection: Protect the product from light and moisture.
• Prohibited: Do not freeze this medicine.
• Shelf-Life: Use the linctus within 3 months after the bottle is first opened.
• Safety: Store the medicine out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired Promethazine Compound Linctus according to local requirements for pharmaceutical waste. Do not dispose of the product in household trash or pour it down a sink or toilet (wastewater).